Table 2.

Baseline associated factors for additional treatment after FAc.

	Mean Final BCVA, ETDRS Letters (SD)	p-Value	Mean BCVA Gain, ETDRS Letters (SD)	p-Value
Baseline <50 letters 50–60 letters >60 letters	41.1 (15.0) letters 60.5 (14.7) letters 74.0 (8.0) letters	p < 0.001	9.7 (10.3) letters 3.6 (11.6) letters −0.5 (6.4) letters	p = 0.02
DME duration <24 months 24–48 months >48 months	65.3 (16.1) letters 77.2 (7.1) letters 62.1 (17.2) letters	p = 0.004	−2.2 (8.4) letters 3.5 (8.0) letters 2.1 (9.5) letters	p = 0.5
DME thickness <300 µm 300–400 µm >400 µm	60.6 (18.0) letters 70.6 (14.4) letters 69.5 (13.3) letters	p = 0.1	2.3 (9.4) letters −1.7 (7.2) letters 8.6 (8.1) letters	p = 0.01
History of vitrectomy Yes No	62.1 (15.4) letters 67.6 (16.7) letters	p = 0.1	0.3 (9.9) letters 2.6 (8.7) letters	p = 0.2
Presence of SD-OCT biomarkers, n (%) SRF IRF HRF DRIL EZ/IZ alterations Hard exudates	78.3 (5.8) letters 66.0 (16.6) letters 68.0 (15.2) letters 57.5 (21.5) letters 58.8 (16.4) letters 65.1 (17.7) letters	p = 0.2 p = 0.8 p = 0.01 p = 0.09 p < 0.001 p = 0.9	10.0 (0.0) letters 1.8 (9.0) letters 1.8 (8.9) letters 1.8 (10.3) letters 2.1 (10.5) letters 2.8 (10.4) letters	p = 0.048 p = 0.4 p = 0.6 p = 0.9 p = 0.9 p = 0.9

BCVA: best corrected visual acuity; CMT: central macular thickness; DME: diabetic macular edema; DRIL: disorganization of retinal inner layers; ETDRS: early treatment diabetic retinopathy study; EZ/IZ: ellipsoid/interdigitation zone; HRF: hyperreflective foci; IRF: intraretinal fluid; SD: standard deviation; SRF: subretinal fluid.